Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NV's quarterly market cap
declined
from Dec. 2025 ($4,013.12 Mil) to Mar. 2026 ($3,733.71 Mil) but then
increased
from Mar. 2026 ($3,733.71 Mil) to Jun. 2026 ($4,181.01 Mil).
NewAmsterdam Pharma Co NV's annual market cap
increased
from Dec. 2023 ($921.19 Mil) to Dec. 2024 ($2,777.24 Mil) and
increased
from Dec. 2024 ($2,777.24 Mil) to Dec. 2025 ($4,013.12 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. NewAmsterdam Pharma Co NV's Enterprise Value for Today is $2,708.49 Mil.
NewAmsterdam Pharma Co NV (NAS:NAMS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
NewAmsterdam Pharma Co NV Market Cap Related Terms
NewAmsterdam Pharma Co NV Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Market Cap distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (NAMS) has a Market Cap of $3,342.26 Mil as of Aug. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #117 out of 1423 companies in the Biotechnology industry, placing it in the top 8.2%.
Is NewAmsterdam Pharma Co NV's Market Cap too high?
NewAmsterdam Pharma Co NV's current Market Cap is $3,342.26 Mil. The Biotechnology industry median Market Cap is 116.70. NewAmsterdam Pharma Co NV's value of $3,342.26 Mil is 2764% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #117 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Market Cap compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #117 out of 1423 companies for Market Cap. This places NewAmsterdam Pharma Co NV in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.70. NewAmsterdam Pharma Co NV's value of $3,342.26 Mil is 2764% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Market Cap of $3,342.26 Mil is 2764% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Market Cap is $3,342.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Market Cap is $3,342.26 Mil and 2764% above the Biotechnology industry median of 116.70. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Market Cap is $3,342.26 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Market Cap: $3,342.26 Mil
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
Industry Position: 2764% above the Biotechnology median (#117 of 1423)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
